Multiple intravenous injections of a cDNA library, derived from human melanoma cell lines and expressed using the highly immunogenic vector vesicular stomatitis virus (VSV), cured mice with established melanoma tumors. Successful tumor eradication was associated with the ability of mouse lymphoid cells to mount a tumor-specific CD4(+) interleukin (IL)-17 recall response in vitro. We used this characteristic IL-17 response to screen the VSV-cDNA library and identified three different VSV-cDNA virus clones that, when used in combination but not alone, achieved the same efficacy against tumors as the complete parental virus library. VSV-expressed cDNA libraries can therefore be used to identify tumor rejection antigens that can cooperate to in...
We have established a model for the immunologic rejection of melanoma cells. Using a receptor-mediat...
Melanoma patients with metastases have a very low survival rate and limited treatment options. There...
Current approaches to cancer immunotherapy include immune checkpoint inhibitors, cancer vaccines, an...
Multiple intravenous injections of a cDNA library, derived from human melanoma cell lines and expres...
Effective cancer immunotherapy requires the release of a broad spectrum of tumor antigens in the con...
Effective cancer immunotherapy requires the release of a broad spectrum of tumor antigens in the con...
Previously, we showed that vesicular stomatitis virus (VSV) engineered to express a cDNA library fro...
A generally applicable, easy-to-use method of focusing a patient's immune system to eradicate o...
Transplantation experiments have demonstrated that most mouse tumors express antigens that can const...
Tumor immunology has come into the limelight since the realization that antitumor cytotoxic T lympho...
Previously, we described VSV-GP, a modified version of the vesicular stomatitis virus, as a non-neur...
We have shown that VSV engineered to express a cDNA library from human melanoma cells (ASMEL, Altere...
Gene therapy strategies, designed to enhance an anti-tumour immune response in patients with melanom...
Summary Clinical observations in the interleukin (IL) 2-based immunotherapies suggest that T cells p...
Cytomegalovirus (CMV) is a ubiquitous herpes virus that generates a unique T cell response, characte...
We have established a model for the immunologic rejection of melanoma cells. Using a receptor-mediat...
Melanoma patients with metastases have a very low survival rate and limited treatment options. There...
Current approaches to cancer immunotherapy include immune checkpoint inhibitors, cancer vaccines, an...
Multiple intravenous injections of a cDNA library, derived from human melanoma cell lines and expres...
Effective cancer immunotherapy requires the release of a broad spectrum of tumor antigens in the con...
Effective cancer immunotherapy requires the release of a broad spectrum of tumor antigens in the con...
Previously, we showed that vesicular stomatitis virus (VSV) engineered to express a cDNA library fro...
A generally applicable, easy-to-use method of focusing a patient's immune system to eradicate o...
Transplantation experiments have demonstrated that most mouse tumors express antigens that can const...
Tumor immunology has come into the limelight since the realization that antitumor cytotoxic T lympho...
Previously, we described VSV-GP, a modified version of the vesicular stomatitis virus, as a non-neur...
We have shown that VSV engineered to express a cDNA library from human melanoma cells (ASMEL, Altere...
Gene therapy strategies, designed to enhance an anti-tumour immune response in patients with melanom...
Summary Clinical observations in the interleukin (IL) 2-based immunotherapies suggest that T cells p...
Cytomegalovirus (CMV) is a ubiquitous herpes virus that generates a unique T cell response, characte...
We have established a model for the immunologic rejection of melanoma cells. Using a receptor-mediat...
Melanoma patients with metastases have a very low survival rate and limited treatment options. There...
Current approaches to cancer immunotherapy include immune checkpoint inhibitors, cancer vaccines, an...